Featured News

Caplacizumab Update

July 2019: Cablivi will shortly be reviewed (by CADTH and INESSS), and recommendations made to Canadian decision makers regarding approval for use and funding. All those diagnosed with TTP are encouraged to help provide the patient perspective to aid decision makers by taking part in the upcoming community survey.
Support Groups

Fall 2018 Ohio TTP & aHUS Support Group Meeting

The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Wednesday November 7th, Dr. Cataland presented a great layman explanation about the role of the ADAMTS13 enzyme in TTP. In addition, he thoughtfully answered questions from both the face-to-face and virtual audiences about TTP triggers, treatments, side effects and more. On an exciting note, he explained the role of a new drug called caplacizumab.